In line with the microarray data, high-risk MDS patients had increased intracellular MSI2 in their CD34+CD38− cells compared with low-risk MDS patients and healthy individuals (Fig. 1c,d). This evidence concerns the gene CD38 and myelodysplastic syndrome.